Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis

Clinical Rheumatology

Volumn 26, Issue 9, 2007, Pages 1517-1521

  Balbir Gurman, Alexandra ^a   Braun Moscovici, Yolanda ^a   Livshitz, Vladimir ^b   Schapira, Daniel ^a   Markovits, Doron ^a   Rozin, Alexander ^a   Boikaner, Tatiana ^c   Nahir, A Menahem ^a  

^a B Shine Department of Rheumatology   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HILLEL YAFFE MEDICAL CENTER   (Israel)

Author keywords

Antioxidants; Catalase; LIloprost; Malondialdehyde; Raynaud's phenomenon; Superoxide dismutase; Systemic sclerosis

Indexed keywords

CATALASE; CERULOPLASMIN; ILOPROST; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; ERYTHROCYTE; FEMALE; FLUSHING; HEMOLYSATE; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; SIDE EFFECT; SYSTEMIC SCLEROSIS; TOOTH PAIN; VASODILATATION; WOUND HEALING;

ADULT; ANTIOXIDANTS; CATALASE; CERULOPLASMIN; FEMALE; HUMANS; ILOPROST; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PLATELET AGGREGATION INHIBITORS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SUPEROXIDE DISMUTASE;

EID: 34547589208     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0613-2     Document Type: Article

References (32)

1. Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine (Baltimore) 59:393-408
2. Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28(1):78-85
3. Maxwell SR, Lip GY (1997) Reperfusion injury: A review of pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol 58(2):95-117
4. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr et al (1994) Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 120(3):199-206
5. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23(5):581-590
6. LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr TA et al (1988) Scleroderma (systemic sclerosis):cLassification, subsets and pathogenesis. J Rheumatol 15:202-205
7. Ravin HA (1961) An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med 58:161-168
8. Aebi H (1974) Catalase. In: Bergmeyer U (ed) Methods of enzymatic analysis. Academic, NY, pp 673-677
9. Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247(10):3470-3475
10. Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride and other halogenoalkanes on peroxidative reactions in rat liver fractions in vitro. Biochem J 123(5):805-814
11. Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39(7):1146-1150
12. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21(8):1477-1483
13. Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S et al (1999) Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol 112(1):78-84
14. Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: Evidence of free radical-mediated injury. Arthritis Rheum 43(4):894-900
15. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44(11):2653-2664
16. Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis. J Exp Med 185(1):71-79
17. Rozen A, Casciola-Rozen L, Wigley F (1997) Role of metal-catalyzed oxidation reactions in the early pathogenesis of scleroderma. Curr Opin Rheumatol 9(6):538-543
18. Musellim B, Ikitimur H, Uzun H, Ongen G (2006) The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int 27(2):163-167
19. Tikly M, Channa K, Theodorou P, Gulimian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25(3):320-324
20. Herrick AL, Matucci Cerinic M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19(1):4-8
21. Das DK, Maulik KN, Moraru II (1995) Gene expression in acute myocardial stress. Induction by hypoxia, ischemia, reperfusion, hyperthermia and oxidative stress. J Mol Cell Cardiol 27(1):181-193
22. Tsan MF (1993) Superoxide dismutase and pulmonary oxygen toxicity. Proc Soc Exp Biol Med 203(3):286-290
23. Pronai L, Arimoni S (1992) Decreased plasma superoxide scavenging activity in immunological disorders-carboxyethylgermanium sesquioxide (Ge-132) as a promoter of prednisolone. Biotherapy 1(4):1-8
24. Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11(3):196-201
25. Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196(1-2):85-91
26. Yamamoto T, Takagawa S, Katayama I, Mizushima Y, Nishioka K (1999) Effect of superoxide dismutase on bleomycin induced dermal sclerosis: implications for the treatment of systemic sclerosis. J Invest Dermatol 113(5):843-847
27. Mizushima Y, Hoshi K, Yanagawa A, Takano K (1991) Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17(2):127-131
28. Niwa Y, Somiya K, Michelson AM, Puget K (1985) Effect of liposomal-encapsulated superoxide dismutase on active oxygen-related human disorders. A preliminary study. Free Radic Res Commun 1(2):137-153
29. Jayson MI, Davis P, Whicher JT, Walters G (1975) Serum copper and caeruloplasmin in ankylosing spondylitis, systemic sclerosis, and morphea. Ann Rheum Dis 35(5):443-445
30. Mittag M, Beckheinrich P, Haustein UF (2001) Systemic sclerosis-related Raynaud's phenomenon: Effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Venereol 81(4):294-297
31. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T et al (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 108(2):241-250
32. Mazzone A, Cusa C, Bucci L, Vezzoli M, Ghio S, Buggia I et al (1999) The effects of iloprost infusion on microcirculation is independent of nitric oxide metabolites and endothelin-1 in chronic peripheral ischaemia. Eur J Clin Invest 29(1):1-5